• Anthera Pharmaceuticals (ANTH) Top-line Phase 3 Results of Sollpura (liprotamase) for Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

       (0 reviews)

    Clinical and Regulatory
    Event Type: Phase 3 Results
    Timing: Q4 2016
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Endocrine
    Indication: Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
    Lead Indication?: No
    Treatment Name: Sollpura (liprotamase)

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Anthera Pharmaceuticals
    Stock Symbol: ANTH
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://investor.anthera.com/releasedetail.cfm?ReleaseID=983643
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement


    Phase 3 SOLUTION Clinical Study Enrollment Target of 126 Patients Met
    We met the enrollment target in our Phase 3 SOLUTION clinical study evaluating the efficacy and safety of the capsule formulation of Sollpura™ to treat exocrine pancreatic insufficiency in patients with cystic fibrosis in early August.  We expect to report topline efficacy data in the fourth quarter of 2016.


      Report Event

    User Feedback

    There are no reviews to display.